Oncimmune makes EarlyCDT-Liver Test commercially available in the U.S.
Category: #health  By Ojaswita Kutepatil  Date: 2018-05-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oncimmune makes EarlyCDT-Liver Test commercially available in the U.S.

Leading early cancer diagnostics company, Oncimmune Holdings PLC, has recently announced that it has launched a liver cancer biopsy platform which is based on its exclusive EarlyCDT liquid biopsy platform technology. Reportedly, the company has completed the development of its EarlyCDT®-Liver test for HCC (hepatocellular carcinoma), which will now be commercially available in the U.S. market.

Sources reveal that EarlyCDT®-Liver is Oncimmune’s second test, after EarlyCDT®-Lung which has shown proven results and has detected cancer up to four years earlier than other methods. The test has high specificity at ninety seven percent which can result into positive test with high degree of certainty.

The high specificity significantly complements the current imaging detection methods as the AFP (alpha fetoprotein) diagnostic test used in Asia.

According to the reliable reports, EarlyCDT®-Liver test is blood test which is complementary to cancer diagnosis via imaging. The test is also expected to aid in the risk assessment & early detection of hepatocellular carcinoma in patients with hepatic lesions not more than 1cm.

EarlyCDT®-Liver will be available through Oncimmune’s current distribution network in the U.S. at the initial stages. The company will further expand its distribution network in the U.S. and other international markets.

Geoffrey Hamilton-Fairley, CEO, Oncimmune, revealed in a company statement that the firm is pleased to announce the commercial availability of EarlyCDT-Liver test. He further exclaimed that a majority of HCC cases are detected in the later stages of the disease or once symptoms appear.

According to Hamilton-Fairley, the test can detect liver cancer in its early stages of development, in turn providing patients with greater chance of more treatment methods and better prognosis.

For the record, liver cancer is 2nd most common cause of cancer deaths across the world. It is particularly more prevalent in Eastern & South-Eastern Asia and is highly associated with smoking, consumption of alcohol, and hepatitis B and C infections.



About Author

Ojaswita Kutepatil

Email: [email protected]   

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, presently develops content for Market Size Forecasters, Algosonline, and other similar platforms. Having had a prior experience in Business Development and Technical Engineering, she now pens down articles pe...

Read More

More News By Ojaswita Kutepatil

Pepperfry to pump $12M in expansion & boost supply chain operations
Pepperfry to pump $12M in expansion & boost supply chain operations
By Ojaswita Kutepatil

The Mumbai-based online retailer also looks to step into areas like augmented/virtual reality to advance shopping experience.

Pepperfry, the online furniture & ...

Dream Incubator leads health-tech firm NIRAMAI’s Series A funding
Dream Incubator leads health-tech firm NIRAMAI’s Series A funding
By Ojaswita Kutepatil

NIRAMAI Health Analytix Pvt. Ltd., the Bengaluru-based breast cancer screening start-up, has reportedly raised around $6 million in Series A investment round that was led by Dream Incubator, a management consulting fir...

Levi Strauss plans share market comeback after more than 3 decades
Levi Strauss plans share market comeback after more than 3 decades
By Ojaswita Kutepatil

In a recent turn of events, renowned Jeans manufacturer Levi Strauss & Co has reportedly filed documents for getting listed on the New York Stock Exchange, on the lookout for returning to public markets after over ...